JP2020523307A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523307A5
JP2020523307A5 JP2019567306A JP2019567306A JP2020523307A5 JP 2020523307 A5 JP2020523307 A5 JP 2020523307A5 JP 2019567306 A JP2019567306 A JP 2019567306A JP 2019567306 A JP2019567306 A JP 2019567306A JP 2020523307 A5 JP2020523307 A5 JP 2020523307A5
Authority
JP
Japan
Prior art keywords
treatment
angiogenesis
intraocular pressure
vegf antagonist
nvg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019567306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523307A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/065464 external-priority patent/WO2018229034A1/en
Publication of JP2020523307A publication Critical patent/JP2020523307A/ja
Publication of JP2020523307A5 publication Critical patent/JP2020523307A5/ja
Pending legal-status Critical Current

Links

JP2019567306A 2017-06-14 2018-06-12 血管新生緑内障を治療するための非抗体ｖｅｇｆアンタゴニスト Pending JP2020523307A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17176072.1 2017-06-14
EP17176072 2017-06-14
PCT/EP2018/065464 WO2018229034A1 (en) 2017-06-14 2018-06-12 Non-antibody vegf antagonists for the treatment of neovascular glaucoma

Publications (2)

Publication Number Publication Date
JP2020523307A JP2020523307A (ja) 2020-08-06
JP2020523307A5 true JP2020523307A5 (enExample) 2021-07-26

Family

ID=59070500

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019567306A Pending JP2020523307A (ja) 2017-06-14 2018-06-12 血管新生緑内障を治療するための非抗体ｖｅｇｆアンタゴニスト

Country Status (4)

Country Link
US (1) US20210138032A1 (enExample)
JP (1) JP2020523307A (enExample)
TW (1) TW201904610A (enExample)
WO (1) WO2018229034A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252079B8 (en) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
NZ770284A (en) 2018-05-10 2025-11-28 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318143T1 (de) 1996-10-25 2006-03-15 Gilead Sciences Inc Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexe
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
JP4723140B2 (ja) 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
DK1767546T3 (da) 2004-06-08 2012-04-23 Chengdu Kanghong Biotechnologies Co Ltd Angiogenese-inhiberende kimært protein og dets anvendelse
RU2550258C2 (ru) 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
WO2014033184A1 (en) 2012-08-28 2014-03-06 Novartis Ag Use of a vegf antagonist in treating ocular vascular proliferative diseases

Similar Documents

Publication Publication Date Title
JP2020523307A5 (enExample)
Bignami et al. NK1 receptor antagonists as a new treatment for corneal neovascularization
Giannaccare et al. Anti-VEGF treatment in corneal diseases
JP2015528454A5 (enExample)
Abdul-Kadir et al. Update on surgical management of complex macular holes: a review
KR102177199B1 (ko) 안저질환 치료제
JP2012072152A5 (enExample)
JP6931046B2 (ja) ｍＴＯＲ阻害剤を含有する黄斑変性治療用薬学組成物
EA032263B1 (ru) Применение ингибиторов ccr3
CA3025258C (en) Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
MX2011001455A (es) Composiciones farmaceuticas oftalmologicas las cuales comprenden sorafenib para el tratamiento de patologias neoangiogenicas del ojo.
CN102105167A (zh) 轴性近视的预防或治疗剂
CN114845718B (zh) 用于治疗与过度血管形成相关的眼部疾病的化合物
WO2018022437A3 (en) Multikinase inhibitors and uses in ocular fibrosis
CN111683682A (zh) 用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物
Oliveira et al. VEGF TrapR1R2 suppresses experimental corneal angiogenesis
TW201904610A (zh) 用於治療新生血管型青光眼之非抗體vegf拮抗劑
RU2575966C2 (ru) Способ лечения неоваскулярной глаукомы
US20080070855A1 (en) Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes
KR20180044237A (ko) 안압 하강 증강제
ES2628321T3 (es) Mejora del resultado de una trabeculectomía
YILMAZ et al. Preoperative Intracameral and Intravitreal Aflibercept Injection, Pars Plana Vitrectomy and Ahmed Glaucoma Valve Implantation in Refractory Neovascular Glaucoma
Abbouda et al. Anterior Segment Diseases
Chanana et al. Premacular subhyaloid haemorrhage in Eales' disease managed with Nd: YAG laser
SHARM et al. Clinical Utilisation of Bevacizumab and Patient Monitoring in Retinal Vein Occlusion and Diabetic Macular Edema